Guess when the price began to ascend from the .30? When Dr. Pierce was hired in December 2013, now add to that the positive news given at ASCO, and where does it stand? Nothing has change, but the value of the company. An employee like Dr. Pierce is a strong asset to them, and investors are more interested in that, than who the CEO is. The young ceo can either learn to run the company towards success, or fail and give up his position, neither one changes what they are trying to achieve.
I think that is the reason everyone is on this, including shorts, no doubt in that. Might as well learn something on the trip and let the facts be the reward.
I think it was more the demand than the buy. MM's stop working at 3 and without them there were not enough shares to cover the demand five minutes to 4. As long as the demand continues to build, this will eventually shift in anticipation to September.
what would you have preferred, in one day? keep in mind that it doubled in one month, which over balances your case. Those seem like growing pains.
for a three year old company with a future ahead the bottom has been built, but the top is what no one knows. And if non responders respond, how high will the pyramid reach? there is no sight.
I understand your timing of bailing out, it was a smart move of the obvious. But nothing has change for the bad. Punit is young, but he is also very eager and has the energy needed to push forward. Personally, I think it was a very smart move in his part to putting the breaks before speeding ahead, while securing the finance needed to accomplish the next step and be encouraged in moving forward. He even took care of the employees future enticements before a shareholders profit.
Would you mind working for some one like him?
not yet, they want to show the big picture, which they are trying to figure out how to explain it. I am guessing the new doctor on board is to help with that. Think about it, if it's not working, why would a renown doctor like Pierce put his life career in jeopardy pursuing something that proved it did not work? “We believe Soldano’s expertise will help us further define the mechanism by which intratumoral electroporation of IL-12 leads to a reversal of these pathologic defects and augments immunogenicity.” Dr. Pierce said. This has been his goal for many years and finally he gets a chance to achieve it. That's what life is about.
Keep an eye on the big picture, they already know it works, but what do they want to do with it?
“Therefore, our goal with ImmunoPulse is to close the gap between non-responders and responders, and let the incredible successes of this class of monoclonal antibodies resonate out to many more of those affected by these devastating diseases.” That's the same with the gap of price just created. We know where this began and where it went with positive news. More news is yet to come.
yes you did, the past catalysts which is the foundation for what's to come. Dr. Pierce said of the data..
“Taken together, these data—the systemic clinical responses, the gene expression pattern in the treated lesions in patients and our analysis of treated and untreated tumors in B16 mouse model—form a coherent picture of IL-12’s mechanism of action as a potent enhancer of tumor immunogenicity. In summary, intratumoral IL-12 appears to ‘de-cloak’ the tumor, allowing the immune system to see the tumor as ‘foreign’ and generate the CD8 T cells needed to mount an attack. These findings are incredibly important given the emerging understanding that a prerequisite for response to T cell checkpoint therapies such as anti -PD-1 mAbs is the presence of the PD-1+ CD8 T cells.”
Now, what are they planning to accomplish with this information is even bigger than what they already have. "As was discussed at ASCO, our technology is demonstrating an ability to enhance these specific biomarkers and convert anti-PD-1 non-responders into responders. We believe this could be game-changing from a clinical perspective, as the majority of late stage melanoma patients (60-80 percent) do not respond to this effective monoclonal antibody treatment, which may soon become standard of care for a variety of cancers. From a business development perspective, expanding the responder population could lead to a significant market opportunity for OncoSec. An important aspect to note is the highly immunogenic nature of melanoma, meaning that the percentage of anti-PD-1 non-responders is likely to be even higher in other types of cancer."
thanks, And I am guessing the new doctor on board is to help with that small problem which takes time, but eventually they will solve. “We believe Soldano’s expertise will help us further define the mechanism by which intratumoral electroporation of IL-12 leads to a reversal of these pathologic defects and augments immunogenicity.” Dr. Pierce said. And once they do, the lowest bid will start with Merk.
Oncs is due for a shift of momentum and that would push it back to a half of a dollar. Many good things are coming this way and it is a matter of time. They are trying to explain it, that which is new to many doctors.
“I was focused on finding a company with a therapeutic approach that would convert anti-PD-1 non-responders into responders. In my opinion, this is the greatest unmet medical need in immune-oncology today.” Now they know it works, but how to explain it?
Dr. Pierce said: “Even if, for example, the ultimate drug of choice might be a monoclonal antibody with a long half-life, one could potentially test whether or not the drug does what you think it will in patients at a fraction of the cost and a fraction of the time required for the development of a recombinant protein or humanized monoclonal antibody.” Imagine how happy the insurance companies will get when they are able to know how to save money, now that they are insuring everyone.
Before, it felt the wind was on the face, now it feels the wind is on the back.
and eventually it will be out. From what is known so far, most likely the trend will continue with good news, and the company will continue to grow. But if someone believes that it might not happen, I understand why they do not trust a young company. But lets not forget, every company starts young, and even though not all grow fast, and some don't grow at all, I hope this one grows faster than us, cause cancer gets closer as time goes by. Just keep an open mind to the science that has been growing way before the company and judge the company after.
how idiotic is this comment, you put down the company, but your advice is to sell now and buy later. Don't worry what other people do with their money, worry about your retirement. Because the truth of the matter is that hopefully we all live long enough to need it. It is obvious you are thinking of the short term, respect the people that are in it for the long run because they are thinking the smart way. If anything try to learn something while you are making a quick buck.
Thanks don, from another article on electroporation (http://www.healio.com/hematology-oncology/hemonc-today-melanoma/il-12-plasmid-electroporation-appears-effective-in-metastatic-melanoma) Dr.Adil Daud said:
“If you were to apply a [direct] current, some pores are opened in the cell membrane and that will force DNA molecules, like plasmids, to enter. The pores are transient — they just last a few thousandths of a second before the cell reseals and heals — but now you have a plasmid inside a cell.” The process is so quick that the DNA or vaccine must be inside the body already through intralesional injections.